CoChat

Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

Mannucci, E., Monami, M., Lamanna, C., Gensini, G. F., Marchionni, N. · 2008 · Diabetes, Obesity and Metabolism
Cited by 103

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aim: The aim of this meta‐analysis of randomized clinical trials (RCT) was to assess whether pioglitazone is also associated with increased cardiovascular risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone were retrieved from Medline (any date up to 31 August 2007; English language only). Unpublished RCT were identified through http://www.clinicaltrials.gov or http://www.fda.gov websites, and results on cardiovascular outcomes were retrieved from investigators and/or sponsors, whenever possible. RCT were included in meta‐analysis if pioglitazone was compared with other treatments (placebo, active comparators or no treatment) for at least 4 weeks. Ninety‐four trials, 10 of which were unpublished, were retrieved; those included in the analysis, which excluded PROspective PioglitAzone Clinical Trial In MacroVascular Events (PROACTIVE), enrolled 11 268 and 9912 patients in the pioglitazone and comparator groups respectively. Data for analysis, extracted independently by two observers, included all‐cause and cardiovascular mortality and incidence of non‐fatal coronary events and heart failure. Proportions of outcome measures across treatment groups were compared by odds ratios (ORs) and 95% confidence interval. Results: Pioglitazone was associated with reduced all‐cause mortality [OR 0.30 (0.14–0.63); p < 0.05], with no relevant effect on non‐fatal coronary events. The observed increase in incidence of non‐fatal heart failure was not statistically significant [OR 1.38 (0.90–2.12)]. Conclusion: The use of pioglitazone does not appear to be harmful in terms of cardiovascular events and all‐cause deaths.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00892.x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 103

Metadata

Authors
Mannucci, E., Monami, M., Lamanna, C., Gensini, G. F., & Marchionni, N.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-10-29
Volume
10
Issue
12
Pages
1221-1238
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2142271188
Cited by
103
References
14
FWCI
9.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00892.x
The paper
Mannucci, E., Monami, M., Lamanna, C., Gensini, G. F., & Marchionni, N. (2008). Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00892.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.